The FDA approved niraparib and abiraterone acetate (Akeega) in combination with prednisone for treating BRCA2-mutated metastatic castration-sensitive prostate cancer (mCSPC), the agency announced on ...
Expanded indication for AKEEGA® (niraparib and abiraterone acetate dual-action tablet) plus prednisone marks the first FDA-approved precision medicine combination treatment for patients with ...
Patients will be able to find out whether they have genes linked to cancer using a world-leading tool developed by the NHS.
Decision making is evidence based and must be shielded from lobbying The NHS draft recommendation against routine prostate cancer screening stems from the conclusion that the harms would outweigh the ...
Thousands of people living with advanced prostate cancer will have access to a life-extending new treatment that can be taken at home from today (Friday, 23 January). NICE has recommended talazoparib ...
Cancer charity highlights apparent ‘postcode lottery’ of testing and diagnoses across different regions seen in study ...
In patients with BRCA2-mutated mCSPC, treatment with Akeega significantly reduced the risk of radiographic progression or death by 54%. The Food and Drug Administration (FDA) has approved Akeega ® ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results